OncoMed Pharmaceuticals, Inc. , a clinical-stage company developing novel therapeutics that target cancer stem cells , or tumor-initiating cells, announced that patient dosing has begun in the double-blinded, placebo-controlled, randomized Phase 2 clinical trial of demcizumab for the treatment of patients with first-line advanced-stage non-small cell lung cancer . "Based on anti-tumor activity and the safety profile observed in our Phase 1b study of demcizumab plus standard-of-care in non-small cell lung cancer, we believe demcizumab has the potential to achieve meaningful clinical benefits for patients with this difficult cancer.
http://ift.tt/1FcYP3z?
http://ift.tt/1FcYP3z?
No comments:
Post a Comment